/ / Software papikostik Software papikostik Name: Software papikostik File size: 822mb Language: English Rating: 1/10 Download software tes papikostik. Spy Undetectable Fee Download. Free software download, The biggest software directory for freeware and shareware. adalah mengakuisisi metode tes PAPI Kostik ke sistem pakar. Software Tes MBTI + Software Tes PAULI + Software Tes EPPS + Software Tes APM +.
7 Sep Papikostick professionsport62.com professionsport62.com PAPIKOstick. Hrg di ubah disc 50 sd 31 des papi kostick software. Screenshots of prueba kostick pdf. David ortiz and jonny gomes walk together before the white house. 18 Jan DISC is a behavior assessment tool based on the DISC theory of psychologist William Moulton Marston, which centers on four different.
ARTIK IoT Modules Family Hub Galaxy Gear Smart TV Z (Tizen Mobile) Program Remote Test Lab professionsport62.com Mobile Tech Insights. MM UNDIP (Master of Management - DIPONEGORO UNIVERSITY) has members. MM Undip is one of the leading business school in Indonesia. Uncontemplated and sports Syd reverse its joggling or tectonically unbarricaded. Sinistrous Teobaldo Yeuk their soal tes papi kostik adumbratively prelects. Free Photo Editing Software.
Buy online or through our helpful. Drivers Software for.
Avast antivirus and anti. Download software tes papikostik.
Professionsport62.com) Home engineering and entertainment professionsport62.com) Design engineering. Norma Alat Tes PAPI Kostik Cuadernillo G3 MSDT Scoring Software for Psychology Contoh Psikogram Dan Laporan Psikotes Level Supervisor. More:.
The Edward Personal Preference Schedule (EPPS) and Fakability. Journal of Applied Psychology, 1958, 42, 22- 27., Caputo, D. V., Psathas, G., and Plapp, J.
Test-Retest Reliability of the EPPS. EDUCATIONAL AND PSYCHOLOGICAL MEASUREMENT, 1966, 26, 883- 886., Edwards, A. Edwards Personal Preference Schedule: Manual. New York: Psychological Corporation, 1959. And Wright, C. The Comparative Reliability of Two Techniques of Personality Appraisal. Journal of Clinical Psychology, 1958, 42, 267- 268.
Self-Ratings and the EPPS. Journal of Applied Psychology, 1959, 15, 388- 391.
Jamiroquai Travelling Without Moving 1996.rar Sony Soho Square XPR 3077, 1996) Cosmic Girl (Quasar.Entering the UK album chart the same week, it's highest position. This Privacy Policy sets out how we will treat any personal information which you provide to us while using the site at (“Site”) or any of the. More Jamiroquai Travelling Without Moving 1996.rar videos Travelling Without Moving is the third studio album released by British funk/acid jazz band Jamiroquai, released on 28 August 1996 in Japan, 9 September 1996 in the. Download FLAC Jamiroquai - Travelling Without Moving 1996 lossless CD, MP3, M4A Travelling Without MovingThe third album by Jamiroquai was released in the UK on 9 September 1996Download File 1996 Jamiroquai Travelling Without Moving rar Download File 1996 Jamiroquai Travelling Without Moving Japan rar Jamiroquai Travelling Without Moving ( Deluxe.
(Extended Mix) – M Beat featuring Jamiroquai. Jamiroquai - Travelling Without Moving - Amazon.com Music. Find album reviews, stream songs, credits and award information for Travelling Without Moving - Jamiroquai on AllMusic - 1996 - Travelling Without Moving deepens the.
Travelling Without Moving by Jamiroquai (CD, Sep-1996, Sony Music Distribution (Email to friends Share on Facebook - opens in a new window or tab Share on Twitter.jamiroquai insanity virtual moving girl cosmic track travelling funk alright albums funky jay heard. Crack Para Black And White 2 Pc put in the description below now pretty. Alright so to fix this you're going to.
You're going to have to enter in these. This video was helpful for you guys. Is that let you go ahead and install it.
You go ahead and fix this as you can see. Alright so the most common issue with it. 8 and 8.1 and 10 so as you can see here. Quick video on how to get black and. Ahead and disabling this Windows Update. Be able to run the game no worries after.
I'm loading the game now yep. Tries to load but never ends up loading. Hey guys leave our owners here with a. Which is causing all the issues so once. Run the game and it just kind of like. Administrator privileges and from there.
Set the flick screens there back to this. And yeah and thanks guys have a good day. Is actually caused by Windows Update it. And then after you install you try to.
White to running on Windows 7 onwards. Have to go into command prompt with. Was released in 2015.
This I've only tested this on Windows 7. Or throws up an error message and this.
Please hit the like button and subscribe. One there you go the game is working if.
Much what this is doing it's just going. But I assume that it'll actually work on. In a second when I get up to it you'll.
Three lines of code which I'm going to 9f3baecc53 lidularbaho. X431 Idiag Crack Software License - X431 Idiag Crack Software License - 2.0 Hardware + Ful. Idiag X431, Wholesale Various High Quality Idiag X431 Products from Global Idiag.Launch X431 iDiag Auto Diag Scanner for Android achieves X431 series. X431 IDiag Software Price. Gts it2 OPCOM MB SD Connect CAT ET License scn coding.How to DIY Get the LAUNCH X431 iDiag Diagnosis Software LAUNCH X431 iDiag is popular auto diangostic tool for DIY user. ADK auto diagnostic has two versions of this.X431 idiag for laptoptop can be used on Android How to activate autocom cdp pro 2012.02.
Launch x431 software crack Launch X431. Like crack, serial.Launch X431 Auto Diag OBD2 scanner is launch diagnostic scan tool. X431 Auto Diag android can be used on Android mobile phone and tablet pc. Launch x431 idiag for.Launch X431 iDiag Auto Diag Scanner for Android achieves X431. Original Launch X431 iDiag Auto. Resolve-the-problem-for-x431-idiag-cannot-buy-single-software.Launch x431 idiag for android.
Software Price: Launch X431 Auto Diag. Wow snooper crash eraser honda transponder key programmer delphi 2015.3 license.key.
How to use Launch X431 iDiag 1. X431 iDiag software complete installation,. And in the Login screen you will see your user name and iDiag Serial No.US$158.00/Piece:Buy Wholesale 2017 New Launch X431 Icarscan Diagnostic Tool Full Systems Replace Launch X431 Idiag Midag Easydiag with 8 Free Software at reasonable.Autodiagnosticobd Launch x431-iv-software-download-update-manual. Launch X431 software update instruction 1. Click LaunchDbs- Dbscar Serial Update Tool.
3).Autosuning is a reliable China OBD2 tools supplier providing Car Truck Diagnostic Tool, Launch X431 Update Software,OBDII EOBD JOBD Scanner, ECU Chip Tunning, Auto.China Launch X431 Software Crack, Launch X431 Software Crack from China Supplier - Find Variety Launch X431 Software Crack from launch x431 pc software,sino crack.X431 iDiag Asia is an integrated service platform based on automotive diagnosis solution.The main functions include car diagnosis, operational data query,2017 New LAUNCH X431 iCarScan Auto Diagnostic Tool Full Systems For Android. Widest carline software.Activation Launch X431 for all vehicles. Launch EASYDIAG,IDIAG,GOLO ACTIVATION for XPRO3 SOFTWARE,.
Launch EASYDIAG,IDIAG,GOLO ACTIVATION for XPRO3. Launch X431 software update instruction 1. Open Dbscar Serial Update Tool. 4) Please tick before the software you want to update, and click.How to use Launch X431 iDiag.
Open App Store. Choose the software of vehicle brand you want to buy. (X431 iDiag Serial Number) iOS operating system:.Thank you for watching. Buy X431 V Get X431 IDIAG Free. Launch X431 V+ Pro Software.Free download Launch X431 update software and update Launch Creader CRP, Launch X431 EasyDiag, LAUNCH X431 5C, LAUNCH X431 V. To the latest version.iDiag Launch X431 is auto diagnostic obd centre. Original iDiag Launch X431 Auto Diag.
Click serial number and in the box of X431 Auto Diag you open the.Auto Parts Warehouse (APW) is an American online retailer of automotive parts and accessories for cars, vans, trucks, and sport utility vehicles. It is one of the flagship websites of U.S.How to register Launch X431 Auto iDiag OBD2 scanner for.
X431 Auto iDiag OBD2 scanner for android. And software download Guide. Launch X431 iDiag for. X431 IDIAG CRACK SOFTWARE 1 day ago. Launch X431 Auto Diag OBD2 scanner x431 idiag for android. Connector serial number will automatically get, if not,.LAUNCH X431 iDiag Auto Diag Scanner for Android.
This is for Launch X431 Auto Diag box ONLY! Software is not included!. You can give us serial number,.Launch X431 iDiag Auto Diag Scanner can diagnose the more than 80 US,.Find the best selection of launch x431 serial number here. Wholesale launch x431 idiag for android. Update,launch x431 android software,new.Untuk pembelian software silahkan kirim ke saya file dari folder CNLAUNCH / EASYIDIAG / SERIAL NUMBER FOLDER 9XXXXXXXXX. Install programm x431 pro 3 di.
UPDATE LAUNCH X431 IDIAG, EASYDIAG,ICARSCAN Pro untuk Android (FULL). Jaminan software akan berjalan sempurna deanga SN idiag atau Easydiang anda.Android application software for X431 iDiag is a telematic application together with vehicle trouble diagnosis and vehicle maintanence news communication.Launch X431 iDiag; Launch Cresetter. X431 serial austford software:. Launch X-431 PAD Universal Auto Diagnostic Scanner 3G WiFi Update Online.Laucnh x431 iDiag V3.0 Download V2.8 Steps:.
Auto Repair Tool.Buy Registered IELTS,TOEFL,ESOL CERTIFICATES Passport,Drivers license,ID Cards,Visas. What to do when you lose your x431 idiag connector.Laucnh x431 iDiag V3.0 Download V2.8 Steps:.
Auto Repair Tool.Original Launch X431 iDiag for IPAD IOS X-431 Auto Diag Scanner Online Update;. Let me show how to install X431 Auto diag software on Iphone.
Download ringtone line chat. The latest version of FunForMobile Ringtones & Chat is 3.22. If you need social network,social media,face book,video chat,online dating,photo sharing,video call,web browser, FunForMobile Ringtones & Chat APK is the best social site,cute guys,dating site,beautiful women,dating apps. FunForMobile Ringtones & Chat is a Social app developed by fun for mobile inc.
Download Windows 7 Fire 32 Bit Iso File Rating: 4,4/5 7037votes Hello Heity, Just a bit of FYI to understand the issues with 32-bit and 64-bit OS upgrades and later options that may or may not be available to you later: When upgrading from Windows Vista to Windows 7 you must upgrade the version currently installed within Windows Vista to the corresponding version in Windows 7. Windows Vista Home Premium to Windows 7 Home Premium; Windows Vista Business to Windows 7 Professional; and Windows Vista Ultimate to Windows 7 Ultimate. You also cannot upgrade a 32-bit operating system to 64-bit - to migrate from 32-bit to 64-bit will require a custom install. Additionally, you will not be able to 'upgrade' from a 32-bit version of Windows 7 to 64-bit - the architecture between the two is too drastically different to allow such a change. To learn more about the differences between a 32-bit operating system and 64-bit please go to the following link: I hope that helps you out!
You can also find lots of information on Windows 7 here in our Springboard website: Thanks again, John M. Microsoft Windows Client Support. Download تحميل win 32 or 86 win 64 Click to expand. Welcome to the Windows 7 Forums website!:ciao: First question is.
Who told you that you need to switch to 32-bit Windows 7? Second, what are the programs you need to run?
Nearly all 32-bit software will run on the Windows 7 64-bit operating system. It even has a 'Programs Folder (x86)' installed in the C drive which is just for 32-bit software. Third, it wouldn't be a driver you need now would it?
That could be an issue. You can't just 'switch' to 32-bit. It is necessary to do a complete clean install because the two versions are not compatible. Different kernals and dlls etc. If you could give us some more information that would be helpful. Hi, I just bought a new laptop a few days ago, with Windows 7 Home Premium installed in it. Sony Downloads For Mac.
But I'm not too sure why I wasn't given a choice to install it as 64 bits instead of 32 bits (the initial laptop they gave me shows that option, but due to some problem, I changed for a new one, right on spot though) And this new one brought me straight to a 32bits setting the moment I turned on the laptop. There are some programs which I wanted to install requires 64 bits, but I can't find any way to solve it, can anyone help me with this? Hi, I just bought a new laptop a few days ago, with Windows 7 Home Premium installed in it.
But I'm not too sure why I wasn't given a choice to install it as 64 bits instead of 32 bits (the initial laptop they gave me shows that option, but due to some problem, I changed for a new one, right on spot though) And this new one brought me straight to a 32bits setting the moment I turned on the laptop. There are some programs which I wanted to install requires 64 bits, but I can't find any way to solve it, can anyone help me with this?
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by sequential progression of pathological events, such as aggregation of amyloid-β proteins, followed by outward symptoms of cognitive impairments. Given that a combination of different therapeutic strategies often provides more rapid and effective outcomes in diverse areas of clinical treatment, we hypothesized that administration of anti-amyloid drugs with cognitive enhancers would result in synergistic effects in AD treatment. Here, we co-administered 4-(2-hydroxyethyl)-1-piperazinepropane-sulphonic acid (EPPS), an amyloid-clearing chemical, and donepezil, an acetylcholinesterase inhibitor, to determine whether they could serve complementary roles for each other in regards to AD treatment. We found that oral administration of these two molecules led to a rapid and consistent cognitive improvement in APP/PS1 transgenic mice.
Although there was no evidence for synergistic effects, our results indicated that EPPS and donepezil function complementary to each other without altering their individual effects. Thus, the combined use of disease-modifying and symptomatic relief drugs may be a promising approach in the treatment of AD. At present, the most common therapeutic options clinically available for Alzheimer’s disease (AD) are acetylcholinesterase inhibitors to provide symptomatic reliefs. Despite benefits of these symptomatic drugs, there is an unmet need to halt the fatal neurodegeneration of AD because neurotoxic pathological markers, such as amyloid-β (Aβ) and tau aggregates, still damage the Alzheimer brain. Many studies have focused on fidning drug candidates that can alter the pathogenesis of AD in the last three decades. Nonetheless, brain atrophy associated with cognitive deficits could not be recovered by modulating pathological culprits. Thus, both disease-modifying and symptomatic relief drugs are necessary as an intervention to effectively treat AD.
We hypothesized that a combination of anti-amyloid and anti-acetylcholinesterase therapeutic strategies would complement each other and result in a relatively prompt symptom improvement along with Aβ clearance taking place in the Alzheimer brain with a sustained symptomatic control owing to the action of the disease-modifying drug. Herein, we administered 4-(2-hydroxyethyl)-1-piperazinepropanesulphonic acid (EPPS), for its disease-modifying effect, and donepezil, for its symptomatic relief, together to aged APPswe/PS1-dE9 (amyloid precursor protein/presenilin protein 1) mice (APP/PS1). This mouse model produces elevated levels of human Aβ by expressing mutant human APP and PS1, which leads to development of Aβ plaques and AD-like cognitive impairments from 6 months of age. EPPS was previously reported to directly disaggregate Aβ oligomers and plaques back into inert monomers in the brains of APP/PS1 mice. Donepezil directly inhibits acetylcholinesterase in the cholinergic synapse to increase acetylcholine concentration in the brain, thereby producing rapid symptomatic relief. During the study, we performed behaviour tests to include Y-maze and fear-conditioning tasks to assess the cognitive recovery of the mice. We also measured the levels of Aβ plaques and oligomers by histochemistry and sandwich enzyme-linked immunosorbent assay (ELISA).
EPPS restores cognitive function of APP/PS1 mice within 4 weeks Aged APP/PS1 model mice (male, 50 weeks of age) and their age-matching wild-type (WT, n = 11) controls were used in this study. The APP/PS1 model is known to show elevated levels of human Aβ by 6–7 months and impaired memory after 8 months of age. In the previous study, we observed clearance of Aβ aggregates and recovery of cognitive impairments in the same mouse model by long-term administration of EPPS in 10, 30 and 100 mg/kg/day. To determine the minimum duration and dosage of EPPS administration for its therapeutic effect, the lower dosages of EPPS (0, 0.1, 1, and 10 mg/kg/day, n = 5, 7, 9, and 9, respectively) were administered orally to APP/PS1 mice daily for 10 weeks. We subjected the mice to weekly Y-maze tests during the EPPS treatment and recorded the sequences of arm entries to analyse the percent alternations reflecting spatial working memory of mice. Two-way repeated measures ANOVA test showed a significant genotype effect ( F(1, 14) = 72.86, P.
EPPS in drinking water was administered to 50-week-old APP/PS1 male mice (water, n = 5; 0.1, 1, and 10 mg/kg/day of EPPS, n = 7, 9, 9) for 10 weeks and compared to age-matched wild type (WT, n = 11). Y-maze tests were performed at every week for 10 weeks. After the last set of Y-maze test, Aβ plaques in brains were stained by thoflavin-S. ( A) Experiment schedule (LOQ: level of quantification).
( B) (%) Alternations of Y-maze tests. Multiple sets of Y-maze tests were analysed by two-way repeated measures ANOVA between wild type and APP/PS1 mice with various EPPS dosages followed by Bonferroni’s post-hoc test (See in for statistical analyses). ( C) Hippocampal region (bregma −1.58−2.18 mm, 6 slides/mouse) of the mouse brain with thoflavin-S staining (scale bar, 400 μm). ( D) Quantifications of number and ( E) area of stained Aβ plaques. ImageJ software was used to quantify numbers and pixel areas of Aβ plaques. Numbers of mice for biochemical analyses are described in Methods.
One-way ANOVA with Bonferroni’s post-hoc comparisons were performed in statistical analyses. All the error bars represent the SEMs. To assess the Aβ clearance by EPPS in the brain, mice were sacrificed after the completion of Y-maze tests and brains were extracted for histochemical analyses. The Aβ plaques in the hippocampus of brain slices (6 slides per mouse) were visualised using thioflavin-S staining (bregma −1.58−2.18 mm). Compared to the non-treated APP/PS1 mice, the amount of Aβ plaques was dramatically reduced in the hippocampal region of APP/PS1 mice treated with 0.1, 1, and 10 mg/kg of EPPS. Quantitative analysis indicated that number and pixel area of Aβ plaques were also decreased in a dose-dependent manner, with EPPS concentration of 0.1, 1 and 10 mg/kg showing significant reductions compared to non-treated APP/PS1 mice (number: P = 0.0298, P.
Donepezil (DNPZ) in drinking water was administered to 50-week-old APP/PS1 male mice (water, n = 9; 0.1 and 1 mg/kg/day of donepezil, n = 6 and 5) for 10 weeks and compared to age-matched wild type (WT, n = 13). Y-maze tests were performed at every week for 10 weeks.
After the last set of Y-maze test, Aβ plaques in brains were stained by thoflavin-S. ( A) Experiment schedule (LOQ: level of quantification). ( B) (%) Alternations of Y-maze tests. Multiple sets of Y-maze tests were analysed by two-way repeated measures ANOVA between wild type and APP/PS1 mice with various donepezil dosages followed by Bonferroni’s post-hoc test (See in for statistical analyses). ( C) Hippocampal region (bregma −1.58−2.18 mm, 6 slides/mouse) of the mouse brain with thoflavin-S staining (scale bar, 400 μm).
( D) Quantifications of number and ( E) area of stained Aβ plaques. ImageJ software was used to quantify numbers and pixel areas of Aβ plaques.
Numbers of mice for biochemical analyses are described in Methods. One-way ANOVA with Bonferroni’s post-hoc comparisons were performed in statistical analyses. All the error bars represent the SEMs. At week 4 and 5, however, efficacy of donepezil started to significantly diminish for both 0.1 and 1 mg/kg compared to WT mice (all P 0.05). The efficacy continued to decrease in donepezil-treated mice, resulting in their percent alternations declining back to the level of non-treated, cognitively impaired APP/PS1 mice group by week 11. Previous study inferred that donepezil has anti-amyloidogenic effects while serving its intended role as a symptomatic drug to alleviate cognitive deficits.
To determine whether donepezil alters the amount of Aβ plaques, mice were sacrificed after the last set of Y-maze tests and brains were extracted and sliced for thioflavin-S staining (6 slides per mouse). Brain images showed decreased amount of Aβ plaques when 1 mg/kg of donepezil was administered to APP/PS1 mice. Quantification analyses showed that area but not number of Aβ plaques were decreased ( P = 0.0072, and P = 0.0115, respectively) compared to non-treated APP/PS1 mice, suggesting that donepezil exhibits weak inhibitory effect against Aβ aggregation.
Software Tes
Collectively, donepezil administration resulted in rapid recovery of cognitive ability within a week, which started to decline gradually over the course of the drug administration. Co-administration of EPPS and donepezil results in rapid and sustained recovery of cognitive function To observe whether EPPS and donepezil are complementary to each other in the AD treatment, we used aged APP/PS1 model mice (male, 50 weeks of age) and their age-matching wild-type (WT, n = 17) controls. APP/PS1 mice were administered with 10 mg/kg of EPPS and 0.1 mg/kg of donepezil – concentrations of which were determined to show substantial effects of drugs based on aforementioned behaviour tests – by drinking water for 11 weeks (n = 9). We performed Y-maze tests weekly from week 0 to 10 during the drug administration. Two-way repeated measures ANOVA test showed a significant genotype effect ( F(1, 27) = 366.80, P. EPPS and donepezil (DNPZ) in drinking water were administered to 50-week-old APP/PS1 male mice (water, n = 12; 10 mg/kg/day of EPPS, n = 8; 0.1 mg/kg/day of donepezil, n = 10; and EPPS/donepezil co-administration, n = 9) for 10 weeks and compared to age-matched wild type (WT, n = 19).
Y-maze tests were performed at every week for 10 weeks. Then, fear-conditioning tests were performed on week 11, and Aβ plaques and oligomers in brains were stained and quantified by thoflavin-S and ELISA, respectively. ( A) Experiment schedule (LOQ: level of quantification). ( B) (%) Alternations of Y-maze tests. Multiple sets of Y-maze tests were analysed by two-way repeated measures ANOVA between wild type and APP/PS1 mice with various mixtures of EPPS and donepezil dosages followed by Bonferroni’s post-hoc test (See in for statistical analyses). ( C) Contextual test and ( D) cued test of fear-conditioning. ( E) Hippocampal region (bregma −1.58−2.18 mm, 6 slides/mouse) of the mouse brain with thoflavin-S staining (scale bar, 400 μm).
( F) Quantifications of number and ( G) area of stained Aβ plaques. ImageJ software was used to quantify numbers and pixel areas of Aβ plaques. ( H) Quantifications of soluble Aβ42 and ( I) insoluble Aβ42 by ELISA analyses (CTX: cortex, HC: hippocampus). Numbers of mice for biochemical analyses are described in Methods. One-way ANOVA with Bonferroni’s post-hoc comparisons were performed in statistical analyses. All the error bars represent the SEMs. After the completion of Y-maze tests, we performed fear-conditioning tests on week 11 to assess the emotion-associated learning ability of mice in a longer time period.
We subjected mice to the contextual test to measure freezing responses related to both hippocampus and amygdala, and performed the cued test to measure freezing responses related to amygdala. In contextual tests , donepezil administration in APP/PS1 mice had no effect in total freezing responses compared to WT mice ( P = 0.0005), suggesting that donepezil does not affect the hippocampal-dependent contextual memory function. These results from contextual tests performed on week 11 are consistent with the declined effect of donepezil we observed in the last set of the Y-maze test. For EPPS-administered APP/PS1 mice, either singly or with donepezil, there were increasing trends of total freezing responses, but they were not statistically significant. In cued tests , APP/PS1 mice administered with either donepezil or EPPS showed trends of increases in total freezing responses, yet they were not statistically significant compared to WT mice.
However, APP/PS1 mice co-administered with EPPS and donepezil showed significantly increased total freezing responses compared to non-treated APP/PS1 mice ( P = 0.0430), suggesting the co-administration improved the amygdala-related memory function of APP/PS1 mice. After the behavioural tests were completed, mice were sacrificed and their brains were extracted to measure the amount of Aβ plaques and oligomers in the brain.
Brain sections were stained with thioflavin-S to visualise Aβ plaques. Compared with non-treated APP/PS1 mice, those treated with either EPPS alone or EPPS with donepezil showed less Aβ plaques. Quantifications of Aβ plaques observed in brain images indicated that number and pixel area of Aβ plaques were significantly lower in these two groups ( P. AD is characterized by severe symptoms of gradual cognitive impairments.
Clinically available for AD patients are symptomatic drugs, such as acetylcholinesterase inhibitors, for dramatic alleviation of the outward symptoms. Yet, given that underlying causes of the disease precede the onset of symptoms, disease-modifying drugs targeting pathological biomarkers, including Aβ plaques and oligomers, would provide further benefits for AD patients. In this study, we examined whether disease-modifying and symptomatic drugs could complement each other when co-administrated in transgenic AD mouse model.
EPPS was used to clear out Aβ aggrega tes from the brain as it was previously found to be safe and tolerable when orally administered to APP/PS1 mice. To alleviate cognitive deficits, donepezil was selected as it has been wildly used in clinics for long period of time and reported with minimal adverse drug reactions. Our results showed that effect of EPPS on cognitive recovery was maintained at an elevated state throughout the period of administration, yet it took several weeks to observe significant effect of the molecule. Given that the previous study of EPPS showed that the AD-like behaviors are highly correlated with the level of Aβ aggregates in the brain, slow effect of the EPPS we observed from APP/PS1 mice could be attributed to the time required to dissemble Aβ aggregates. On the other hand, donepezil administration led to more prompt behavioural changes that APP/PS1 mice showed cognitive recovery; however, its effect was transient, possibly due to the progression of the disease even with the use of the symptomatic drug. Co-administration of EPPS and donepezil was aimed at simultaneously targeting pathological and symptomatic reliefs, and it resulted in rapid and sustained cognitive recovery, suggesting that two molecules of different modes of actions complemented each other. Drug-drug interactions must be considered during the development of cocktail therapy.
Despite the absence of synergic effects between EPPS and donepezil, their co-administration did not reduce or alter each other’s therapeutic effects on cognition. Additional studies are warranted to determine whether co-administration of EPPS and donepezil could deliver therapeutic effects to AD patients. Reagents 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS), donepezil hydrochloride monohydrate, thioflavin-S, and protease inhibitor cocktail were from Sigma-Aldrich (St. Deionized water was generated by a Milli-Q plus from Millipore (Bedford, MA). A RIPA buffer and phosphate buffered saline (PBS buffer) were purchased from ThermoFisher. (Roxkford, IL).
Immunoassay kits for insoluble fraction of Aβ quantifications were used from Invitrogen (KHB3442, Camarillo, CA). AD transgenic mice preparation Doubly mutated transgenic mice (male), originally obtained from Jackson Laboratory (USA; strain name: B6C3-Tg (APPswe/PS1-dE9) 85Dbo/J; stock number 004462), were supplied from Hanmi Pharm Co., Ltd. (Gyeonggi, Korea) and Medifron DBT (Gyeonggi, Korea). These APP/PS1 transgenic mice were maintained as double hemizygotes by crossing with wild type mice on a C57BL/6J × C3H backgrounds train. All mice were housed 4 to 5 per plastic cage in a room maintained at 21 ± 1 °C, with an alternating 12 hr light-dark cycle and free access to food and water. Behavioural experiments were carried out in a sound-attenuated and air-regulated experiment room, following at least 30 min of habituation time. All of the animal experiments were carried out in accordance with the National Institutes of Health guide for the care and use of laboratory animals (NIH Publications No.
8023, revised 1978). The animal studies were approved by the Institutional Animal Care and Use Committee of Korea Institute of Science and Technology.
EPPS and donepezil administration EPPS and donepezil in drinking water were freely administered for about 3 months (11–12 weeks) with different dosage (0.1, 1, or 10 mg/kg) to 12-month-old (50 weeks of age) wild type and APP/PS1 transgenic male mice exhibiting severe AD-like behaviours and Aβ plaque deposits in brains. For the exact administration of EPPS and donepezil, their dosages were calculated based on the average daily water consumption recorded in each cage, and they were confirmed by re-calculations once a week. Fresh drinking water was provided daily.
The experimental schedule is shown in, and. Over the course of the oral administration, we performed Y-maze tests every week to examine the efficacy of drugs and performed fear-conditioning tests after the last set of Y-maze. After all behaviour tests, mice were sacrificed for further biochemical analyses. Numbers of mice used in the experiments of EPPS administration were: 11 (WT, water), 5 (APP/PS1, water), 7 (APP/PS1, 0.1 mg/kg/day), 9 (APP/PS1, 1 mg/kg/day), and 9 (APP/PS1, 10 mg/kg/day).
Numbers of mice used in the experiments of donepezil administration were: 13 (WT, water), 9 (APP/PS1, water), 6 (APP/PS1, 0.1 mg/kg/day), and 5 (APP/PS1, 1 mg/kg/day). Numbers of mice used in the experiments of EPPS/donepezil co-administration were: 17 (WT, water), 12 (APP/PS1, water), 8 (APP/PS1, 10 mg/kg/day of EPPS), 10 (APP/PS1, 0.1 mg/kg/day of donepezil), and 9 (APP/PS1, 10/0.1 mg/kg/day of EPPS/donepezil). Multiple trials of Y-maze test Y-maze test is used to assess cognitive changes and short-term spatial working memory (by spontaneous alternation) and exploratory activity (by total number of arm choices) of mice placed into a black Y-maze. The Y-maze is a three-arm horizontal maze (40 cm-long and 10 cm-wide with 12 cm-high walls) in which the arms are symmetrically disposed at 120° angles from one another.
Mice were placed at the end of one arm and allowed to move freely through the maze during an 8-min session. The number of total arm choices and sequence of arm choices were recorded.
The percent alternation is defined by proportion of arm choices that differ from the last 2 choices. Before each trial, the interior of the maze was sprayed with a 70% ethanol solution to erase any scent cues. To evaluate the efficacy of drugs in a time-dependent manner, Y-maze tests were performed every week during the drug administration periods.
Fear conditioning test Fear-conditioning test measures the ability of mice to learn and remember an association between aversive experience and environmental cue. The hippocampal lesions interfere with contextual conditioning but not the cued, whereas amygdala lesions interfere with both contextual and cued conditionings. Both contextual and cued tasks were carried out 4 days after the last set of Y-maze test. On the first day, mice were placed into a cued box for 5 min to habituate and explore.
Next day, for training (fear-conditioning phase), mice were placed into a sound-attenuating standard operant chamber (Coulbourn, USA). After 3 min of adjustment in the chamber, 30-sec of tone (3 kHz, 85 dB) was delivered with a foot shock (0.5 mA) at the last 1 sec of tone stimulus.
This training was repeated two times continuously with 90-sec intervals. After 24 hr, mice were subjected to the same chamber for contextual retention test. Its movements were recorded using a video camera for 5 min to score freezing responses, which were defined as lack of movements except for respiration.
Cued fear-conditioning was performed on the final day of fear conditioning study. After placed into the cued box, mice were allowed to explore for 3 min and the conditioning tone was delivered for 1 min. The responses were recorded using a video camera to score freezing. Thioflavin-S staining After the behaviour tests, mice were deeply anesthetized with a blend of tiletamine. HCl, zolazepam. HCl (80 mg/kg, IP, Zoletil 50®, Virbac, France), and xylazine (20 mg/kg, IP, Rompun®, Bayer Pharma, Germany) and perfused with 0.9% saline followed by ice-cold 4% paraformaldehyde.
Excised brains were post-fixed overnight in 4% paraformaldehyde at 4 °C and immersed in 30% sucrose for 48 hr for cryoprotection. Coronal sections (6 slides/animal) of the brain (30 μm) were cut with a Cryostat (Microm HM 525, Thermo Scientific, Walthman, MA, USA) and stained with thioflavin-S, which wasprepared at 500 μM in 50% of ethanol, for 7 min to visualise Aβ plaques.
Then, brain sections were soaked sequentially into 100, 95 and 90% of ethanol for 10 sec and then moved into PBS to remove a non-specific binding of the dye. The images of hippocampal region along the AP axis (bregma −1.58−2.18 mm) were taken on an Olympus fluorescent microscope using a GFP filter set.
ImageJ software was used to quantify numbers and pixel areas of Aβ plaques. Numbers of mice used in the brain staining of EPPS administration were: 5 of 11 (WT, water), 2 of 5 (APP/PS1, water), 3 of 7 (APP/PS1, 0.1 mg/kg/day), 4 of 9 (APP/PS1, 1 mg/kg/day), and 4 of 9 (APP/PS1, 10 mg/kg/day). Numbers of mice used in the brain staining of donepezil administration were: 6 of 13 (WT, water), 4 of 9 (APP/PS1, water), 3 of 6 (APP/PS1, 0.1 mg/kg/day), and 2 of 5 (APP/PS1, 1 mg/kg/day). Numbers of mice used in the brain staining of EPPS/donepezil co-administration were: 8 of 17 (WT, water), 6 of 12 (APP/PS1, water), 4 of 8 (APP/PS1, 10 mg/kg/day of EPPS), 5 of 10 (APP/PS1, 0.1 mg/kg/day of donepezil), and 4 of 9 (APP/PS1, 10/0.1 mg/kg/day of EPPS/donepezil).
Quantifications of the Aβ levels Levels of soluble and insoluble Aβ were quantified following the procedures of Kawarabayashi et al. Hippocampal and cortical regions of the brain were dissected separately and homogenized in ice-cold lysis buffer, RIPA, containing 1x protease inhibitors cocktail. Homogenized tissues were incubated in ice for 20 min and centrifuged at 14,000 rpm, 4 °C for 30 min.
The supernatant (soluble fraction) of brain lysates was analyzed with Aβ42 ELISA kit purchased from Invitrogen (KHB3442). To obtain Aβ insoluble fraction in brain lysates, a guanidine buffer (5 mM guanidine-HCl, 50 mM Tris-HCl, pH 8.0) containing 1x protease inhibitors cocktail was added to the pellet of brains lysates and incubated at room temperature for 3 hr with shaking. Then, the mixture was centrifuged at 4 °C for 2 hr to obtain Aβ insoluble fraction in supernatant. Levels of insoluble fractions were measured using the Aβ42 ELISA kit. Protein concentrations of soluble and insoluble fractions were determined by Bradford protein assay.
Download Software Tes Epps
Based on the results, 20 μg of soluble and 10 μg of insoluble fractions were used for ELISA analyses. Numbers of mice used in the brain lysates of EPPS administration were: 6 of 11 (WT, water), 3 of 5 (APP/PS1, water), 4 of 7 (APP/PS1, 0.1 mg/kg/day), 5 of 9 (APP/PS1, 1 mg/kg/day), and 5 of 9 (APP/PS1, 10 mg/kg/day). Numbers of mice used in the brain lysates of donepezil administration were: 7 of 13 (WT, water), 5 of 9 (APP/PS1, water), 3 of 6 (APP/PS1, 0.1 mg/kg/day), and 3 of 5 (APP/PS1, 1 mg/kg/day). Numbers of mice used in the brain lysates of EPPS/donepezil co-administration were: 9 of 17 (WT, water), 6 of 12 (APP/PS1, water), 4 of 8 (APP/PS1, 10 mg/kg/day of EPPS), 5 of 10 (APP/PS1, 0.1 mg/kg/day of donepezil), and 5 of 9 (APP/PS1, 10/0.1 mg/kg/day of EPPS/donepezil). Statistical analysis Graphs were obtained with GraphPad Prism 6.
Data from multiple sets of Y-maze tests were analysed by two-way repeated measures ANOVA with Bonferroni’s post-hoc comparisons. Data from other tests were analysed by one-way ANOVA with Bonferroni’s post-hoc comparisons (. P. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291, 317–324, doi: 10.1001/jama.291.3.317 (2004). 2. H., Hoblyn, J., Mohanty, S.
Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 289, 210–216 (2003).
Software Tes Buta Warna
3. Sinforiani, E., Banchieri, L. M., Zucchella, C., Bernasconi, L. Cholinesterase inhibitors in Alzheimer’s disease: efficacy in a non-selected population.
Funct Neurol 18, 233–237 (2003). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370, 322–333, doi: 10.1056/NEJMoa1304839 (2014). 5. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease.
N Engl J Med 370, 311–321, doi: 10.1056/NEJMoa1312889 (2014). 6. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade.
Lancet Neurol 9, 119–128, doi: 10.1016/S1474-449-6 (2010). 7. EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-beta oligomers and plaques.
Nat Commun 6, 8997, doi: 10.1038/ncomms9997 (2015). 8. Cao, D., Lu, H., Lewis, T.
Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 282, 2, doi: 10.1074/jbc.M703561200 (2007). 9. Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes. Core Evid 1, 195–219 (2006).
J., Lee, H., Perry, G., Smith, M. & Casadesus, G. In Methods of Behavior Analysis in Neuroscience Frontiers in Neuroscience (ed Buccafusco, J. Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation. Neuroscience 290, 530–542, doi: 10.1016/j.neuroscience.2015.01.058 (2015). 12. Galimberti, D.
& Scarpini, E. Disease-modifying treatments for Alzheimer’s disease. Ther Adv Neurol Disord 4, 203–216, doi: 10.11611404470 (2011). 13. A., Mitchell, S.
Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer’s disease: systematic review of the ‘real-world’ evidence. Dement Geriatr Cogn Disord 28, 389–403, doi: 10.1178 (2009). 14. The behavioural effects of levallorphan, cyprenorphine (M285) and amphetamine on repeated Y-maze performance in rats.
Psychopharmacologia 21, 257–267 (1971). 15. Contextual conditioning with massed versus distributed unconditional stimuli in the absence of explicit conditional stimuli. J Exp Psychol Anim Behav Process 14, 187–199 (1988). 16.
Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106, 274–285 (1992).
17. Li, Z., Herrmann, K. & Pohlenz, F. Lateral scanning confocal microscopy for the determination of in-plane displacements of microelectromechanical systems devices.
Opt Lett 32, 1743–1745 (2007). 18. Kawarabayashi, T. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurosci 21, 372–381 (2001). Author notes. Hye Yun Kim.
& Hyunjin Vincent Kim These authors contributed equally to this work. Affiliations. Convergence Research Center for Dementia and Center for Neuro-Medicine, Brain Science Institute, Korea Institute of Science and Technology, Hwarangno 14-gil 5, Seongbuk-gu, Seoul, Republic of Korea.
Hye Yun Kim., Hyunjin Vincent Kim., Dongkeun K. Lee., Seung-Hoon Yang. & YoungSoo Kim. Biological Chemistry Program, Korea University of Science and Technology, 217 Gajungro, Yuseong-gu, Daejeon, Republic of Korea. Hye Yun Kim., Hyunjin Vincent Kim. & YoungSoo Kim. Department of Pharmaceutical Science, College of Pharmacy, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, Republic of Korea.
YoungSoo Kim.
Comments are closed.
|
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |